Article in Molecular cancer therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors at 3 institutions in 3 countries.
Xing Wang *Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5274-5659
Natasha Raman *Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0002-8872-0613
Ghali Lemtiri-Chlieh *Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0002-2406-3618
Jinhee ChangDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0002-3603-403X
Shreya JagtapDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0001-7864-5587
Dipanwita Dutta ChowdhuryDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0001-8314-7371
Matthew BallewDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0002-4574-9950
Francesca Anna CarrieriDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0001-7881-1581
Triet NguyenDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0003-0556-051X
Katriana NugentDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0001-5062-4135
Travis PeckDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0001-9041-5776
Michelle S LevineDepartment of Molecular Biology and Genetics, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0002-7220-8930
Aaron ChanDepartment of Radiation Oncology, Division of Translational Radiation Sciences, University of Maryland Baltimore, School of Medicine, Baltimore, Maryland.ORCID 0000-0002-6239-408X
Christine LamDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0002-6393-8237
Reem MalekDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0001-5346-1431
Tung HoangDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0002-4300-9692
Ryan PhillipsDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4895-9838
ZhuoAn ChengDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4257-8487
Kekoa TaparraDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0001-8493-3868
Nick ConnisDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0001-5725-0674
Christine L HannDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0002-1467-5557
Andrew HollandDepartment of Molecular Biology and Genetics, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3728-6367
Phuoc T TranDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0002-0147-0376
Audrey Lafargue *Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0001-9551-2815
Hailun Wang *Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, School of Medicine, Baltimore, Maryland.ORCID 0000-0001-8651-2856
Johns Hopkins University · USUniversity of Maryland, Baltimore · USMayo Clinic · US
Funding
Resource Sharing CoreU54CA273956 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Phuoc T. Tran · 2022 to 2026
$8.9M
Tumor-barcoding coupled with high-throughput sequencing of a novel chemoradiation resistant SCLC mouse modelU01CA231776 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANN, CHRISTINE L., MARCHIONNI, LUIGI · 2018 to 2022
$3.9M
Centrosome biogenesis and copy number controlR01GM114119 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI CORMACK, BRENDAN · 2015 to 2023
$3.3M
Integrating bioinformatics into multiscale models for hepatocellular carcinomaU01CA212007 · NCI · JOHNS HOPKINS UNIVERSITY · PI EWALD, ANDREW JOSEF, FERTIG, ELANA · 2018 to 2022
$3.2M
The role of TRIM37 in driving tumorigenesis and cancer-specific vulnerability to PLK4 inhibitionR01CA266199 · NCI · JOHNS HOPKINS UNIVERSITY · PI Sergi Regot · 2022 to 2026
$2.7M
Molecular mechanism that suppresses the proliferation of cells with supernumerary centriolesR01GM133897 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI CORMACK, BRENDAN · 2019 to 2022
$1.9M
Mechanisms of TWIST1-induced sorafenib resistance in liver CAF31CA189588 · NCI · JOHNS HOPKINS UNIVERSITY · PI TAPARRA, KEKOA · 2014 to 2015
$84k
Anonymous donorJohns Hopkins and Allegheny HealthNCI NIH HHS F31 CA189588NCI NIH HHS R01 CA266199NCI NIH HHS U01 CA212007NCI NIH HHS U01 CA231776NCI NIH HHS U54 CA273956NIGMS NIH HHS R01 GM114119NIGMS NIH HHS R01 GM133897Prostate Cancer Foundation (PCF)Radiological Society of North America (RSNA)Uniting Against Lung CancerU.S. Department of Defense (DOD) W81XWH-18-1-0435U.S. Department of Defense (DOD) W81XWH-21-1-0296
6 · The paper itself
Abstract
Extra copies of centrosomes are frequently observed in cancer cells. To survive and proliferate, cancer cells have developed strategies to cluster extra-centrosomes to form bipolar mitotic spindles. The aim of this study was to investigate whether centrosome clustering (CC) inhibition (CCi) would preferentially radiosensitize non-small cell lung cancer (NSCLC). Griseofulvin (GF; FDA-approved treatment) inhibits CC, and combined with radiation treatment (RT), resulted in a significant increase in the number of NSCLC cells with multipolar spindles, and decreased cell viability and colony formation ability in vitro. In vivo, GF treatment was well tolerated by mice, and the combined therapy of GF and radiation treatment resulted in a significant tumor growth delay. Both GF and radiation treatment also induced the generation of micronuclei (MN) in vitro and in vivo and activated cyclic GMP-AMP synthase (cGAS) in NSCLC cells. A significant increase in downstream cGAS-STING pathway activation was seen after combination treatment in A549 radioresistant cells that was dependent on cGAS. In conclusion, GF increased radiation treatment efficacy in lung cancer preclinical models in vitro and in vivo. This effect may be associated with the generation of MN and the activation of cGAS. These data suggest that the combination therapy of CCi, radiation treatment, and immunotherapy could be a promising strategy to treat NSCLC.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS. · full record | OpenQuestion